Search results for "Psoriatic"

showing 10 items of 73 documents

A 588-gene microarray analysis of the peripheral blood mononuclear cells of spondyloarthropathy patients

2002

OBJECTIVES: To identify genes which are more highly expressed in the peripheral blood mononuclear cells (PBMC) of patients with spondyloarthropathy (SpA), rheumatoid arthritis (RA) and psoriatic arthritis (PsA), in comparison to normal subjects. METHODS: A 588-gene microarray was used as a screening tool to select a panel of such genes from PBMC of these subjects and of normal subjects. Results were then validated by reverse transcription-polymerase chain reaction (RT-PCR). RESULTS: The following genes were more highly expressed in arthritis patients than in normal subjects: macrophage differentiation marker MNDA (myeloid nuclear differentiation antigen), MRP8 and MRP14 (migratory inhibitor…

AdultGenetic MarkersMaleCCR1Receptors CXCR4AdolescentSpondyloarthropathyArthritisPeripheral blood mononuclear cellArthritis RheumatoidPsoriatic arthritisRheumatologymedicineHumansSpondylitis AnkylosingPharmacology (medical)AgedOligonucleotide Array Sequence AnalysisReverse Transcriptase Polymerase Chain Reactionbusiness.industryJanus kinase 3Arthritis PsoriaticSynovial MembraneMNDAInterleukinDNAMiddle Agedmedicine.diseaseAntigens DifferentiationChemokine CXCL12ImmunologyLeukocytes MononuclearFemalebusinessChemokines CXCRheumatology (Oxford, England)
researchProduct

Real-world evidence of biologic treatments in psoriatic arthritis in Italy: results of the CHRONOS (EffeCtiveness of biologic treatments for psoriati…

2022

Abstract Background Biologics have demonstrated efficacy in PsA in randomized clinical trials. More evidence is needed on their effectiveness under real clinical practice conditions. The aim of the present work is to provide real-world evidence of the effectiveness of biologics for PsA in the daily clinical practice. Methods CHRONOS was a multicenter, non-interventional, cohort study conducted in 20 Italian hospital rheumatology clinics. Results 399 patients were eligible (56.9% females, mean (SD) age: 52.4 (11.6) years). The mean (SD) duration of PsA and psoriasis was 7.2 (6.9) and 15.3 (12.2) years, respectively. The mean (SD) duration of the biologic treatment under analysis was 18.6 (6.…

TNF-inhibitors.ACRBiologicRheumatologyPsoriatic arthritiDAS28Real world evidenceSecukinumabBMC Rheumatology
researchProduct

Targeted synthetic disease-modifying antirheumatic drugs in spondyloarthritis

2017

medicine.medical_specialtyImmunologyDisease03 medical and health sciencesPsoriatic arthritis0302 clinical medicineHumansImmunology and AllergyMedicineSpondylitis AnkylosingMolecular Targeted TherapyProtein Kinase Inhibitors030203 arthritis & rheumatologyClinical Trials as TopicTofacitinibbusiness.industrymedicine.diseaseDermatologyOncologyNilotinibAntirheumatic Agents030220 oncology & carcinogenesisApremilastbusinessAntirheumatic drugsmedicine.drugImmunotherapy
researchProduct

The Respiratory Burst and Psoriasis

1988

Psoriasis is a disease affecting about 1–2% of the population worldwide, similar to diabetes mellitus.1 It occurs somewhat more frequently in the white population than among Asians and Eskimos.1 The disease has two peaks of onset, an early one occurring around the age of 20 and a later one around 60.2 In early-onset psoriasis, 85% of patients exhibit the HLA Cw6 antigen; in the late-onset group, no such pattern of inheritance can be found.2

education.field_of_studymedicine.medical_specialtybusiness.industryPopulationDiseasemedicine.diseaseDermatologyRespiratory burstPsoriatic skinAntigenDiabetes mellitusWhite populationPsoriasismedicineeducationbusiness
researchProduct

Metabolomics: An Emerging Approach to Understand Pathogenesis and to Assess Diagnosis and Response to Treatment in Spondyloarthritis

2022

Spondyloarthritis (SpA) is a group of rheumatic diseases whose pathogenesis relies on a complex interplay between genetic and environmental factors. Over the last several years, the importance of the alteration of the gut microbiota, known as dysbiosis, and the interaction of bacterial products with host immunity have been highlighted as intriguing key players in SpA development. The recent advent of the so called “-omics” sciences, that include metabolomics, opened the way to a new approach to SpA through a deeper characterisation of the pathogenetic mechanisms behind the disease. In addition, metabolomics can reveal potential new biomarkers to diagnose and monitor SpA patients. The aim of…

psoriatic arthritisQH301-705.5MicrobiotaPsoriatic arthritibiomarkersMetabolomicBiomarkerGeneral MedicineGastrointestinal MicrobiomeAnkylosing spondylitistomatognathic diseasesankylosing spondylitisSpondyloarthritisSpondylarthritisDysbiosisHumansMetabolomicsSpondylitis AnkylosingBiology (General)Cells
researchProduct

Assessment of Periodontal status in Patients with Psoriatic Arthritis : a retrospective, case-control study

2021

Background Psoriatic arthritis (PsA) and periodontitis both represent chronic inflammatory disorders that share similar pathophysiological processes. However, very few studies have been done to address the link between the two diseases which remains poorly understood. The present study aimed to assess and compare the periodontal status in patients suffering from PsA and systemically healthy subjects to identify whether a possible association exists between PsA and periodontitis. Material and Methods Periodontal parameters – PI, BOP, mGI, PPD and CAL were recorded in 110 patients with PsA and 110 age- and gender-matched systemically healthy patients. Mean values of the periodontal parameters…

Periodontitismedicine.medical_specialtybusiness.industryResearchCase-control studymedicine.diseaseLogistic regressionPathophysiologyPsoriatic arthritisClinical attachment lossInternal medicinemedicinePeriodontologyIn patientStage (cooking)businessGeneral DentistryUNESCO:CIENCIAS MÉDICAS
researchProduct

TAP-polymorphisms in juvenile onset psoriasis and psoriatic arthritis.

1996

Abstract Juvenile onset psoriasis is strongly associated with the HLA-class I genes Cw6 and B57 whereas patients with psoriatic arthritis show an increased frequency of HLA-B27. It is unclear whether additional major histocompatibility genes also increase disease susceptibility. The TAP genes (transporter associated with antigen processing) encode two membrane-spanning proteins that translocate antigenic peptides from the cytoplasm into the endoplasmic reticulum. Comparison of 60 patients with juvenile onset psoriasis, 63 psoriatic arthritis patients, and 101 caucasoid controls revealed an increase of the TAP1 ∗ 0101 allele in the psoriasis group, that could not be explained by linkage to o…

ImmunologyLinkage DisequilibriumMajor Histocompatibility ComplexPsoriatic arthritisATP Binding Cassette Transporter Subfamily B Member 3PsoriasismedicineImmunology and AllergyHumansPsoriasisAlleleATP Binding Cassette Transporter Subfamily B Member 2GenePolymorphism Geneticbiologybusiness.industryEndoplasmic reticulumArthritis PsoriaticHistocompatibility Antigens Class IGeneral MedicineTransporter associated with antigen processingHLA-DR Antigensmedicine.diseaseImmunologybiology.proteinTAP2ATP-Binding Cassette TransportersTAP1businessHuman immunology
researchProduct

FRI0162 IL-9 Over-Expression and Th9 Polarization Immunologically Characterizes the Subclinical Gut Inflammation of Patients with Psoriatic Arthritis

2014

Background Subclinical gut inflammation has been demonstrated in patients with psoriatic arthritis (PsA) suggesting a role for the gut in the pathogenesis of inflammation in these patients. A key role for the IL-23, IL-17, IL-22 and IL-9 in the pathogenesis of psoriasis and psoriatic arthritis has been suggested, the immunologic abnormalities underlying subclinical gut inflammation in PsA are still undefined however. Objectives This study was undertaken to investigate the expression and tissue distribution of IL-23 and of Th17,Th22 and Th9 related molecules in the subclinical gut inflammation of patients with PsA. Methods Gut inflammation was assessed accordingly to De Vos et al (1). Quanti…

Pathologymedicine.medical_specialtybusiness.industryImmunologyHigh endothelial venulesInflammationHyperplasiamedicine.diseaseGeneral Biochemistry Genetics and Molecular BiologyPathogenesisPsoriatic arthritisImmune systemRheumatologyPsoriasisImmunologymedicineImmunology and Allergymedicine.symptombusinessSubclinical infectionAnnals of the Rheumatic Diseases
researchProduct

Reply

2017

Settore MED/16 - ReumatologiaArthritis PsoriaticInterleukin-9Human
researchProduct

Differential association of polymorphisms in the TNFalpha region with psoriatic arthritis but not psoriasis.

2002

To investigate the potential association of tumour necrosis factor alpha (TNFalpha) microsatellite and promoter alleles with psoriatic arthritis (PsA).DNA from 89 white patients with PsA, 65 patients with psoriasis, and 99 healthy white controls was investigated for two TNFalpha promoter (-238 and -308) and three microsatellite polymorphisms (TNFa, c, and d). Patients had previously been studied by serology for HLA class I antigens and by sequence-specific polymerase chain reaction for DRB1* alleles. In addition, TNFalpha production of Ficoll separated peripheral blood mononuclear cells (PBMC) into culture supernatants after stimulation with lipopolysaccharide, alphaCD3 antibodies, phytohae…

AdultMaleImmunologyArthritisEnzyme-Linked Immunosorbent AssayHuman leukocyte antigenurologic and male genital diseasesPeripheral blood mononuclear cellPolymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyStatistics NonparametricPsoriatic arthritisRheumatologyPsoriasismedicineOdds RatioImmunology and AllergyHumansPsoriasisPromoter Regions GeneticAllelesCells CulturedPhytohaemagglutininAgedAged 80 and overChi-Square DistributionPolymorphism Geneticbiologybusiness.industryTumor Necrosis Factor-alphaHaplotypeArthritis PsoriaticMiddle Agedmedicine.diseaseExtended ReportCase-Control StudiesImmunologybiology.proteinLeukocytes MononuclearFemaleAntibodybusinessMicrosatellite RepeatsAnnals of the rheumatic diseases
researchProduct